| Literature DB >> 32117022 |
Ruoyao Cao1,2, Gengfan Ye3,4, Rui Wang2, Lei Xu5, Yun Jiang5, Guoxuan Wang2, Daming Wang3, Juan Chen2.
Abstract
Objective: Although the benefits of good collateral circulation on infarct volume and outcomes have been confirmed in previous studies, few studies have investigated the relationship between hemorrhagic transformation (HT) and collateral circulation in acute ischemic stroke (AIS). This study aimed to assess whether collateral circulation is an essential factor of HT after endovascular treatments (EVTs).Entities:
Keywords: 4D CTA; collateral circulation; endovascular treatment; hemorrhagic transformation; stroke
Year: 2020 PMID: 32117022 PMCID: PMC7019033 DOI: 10.3389/fneur.2020.00060
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Baseline clinical and imaging characteristics.
| Clinical data | |||
| Age (years), mean ± SD | 77.17 ± 8.07 | 68.85 ± 12.70 | <0.001 |
| Male, | 15 (50.00) | 22 (53.70) | 0.761 |
| NIHSS, median (IQR) | 18.50 (14.00, 21.50) | 14.00 (8.00, 16.00) | <0.001 |
| SBP (mm Hg) | 160.57 ± 24.48 | 139.80 ± 23.87 | 0.001 |
| DBP (mm Hg) | 84.64 ± 13.86 | 79.95 ± 15.43 | 0.192 |
| Risk factors, | |||
| AF history | 20 (66.70) | 18 (43.90) | 0.057 |
| Hypertension | 26 (86.70) | 29 (70.70) | 0.110 |
| Diabetes mellitus | 14 (46.70) | 16 (39.00) | 0.520 |
| Hyperlipidemia | 18 (60.00) | 15 (36.60) | 0.051 |
| Smoking | 11 (36.70) | 14 (34.10) | 0.826 |
| Previous stroke | 9 (30.00) | 13 (31.70) | 0.878 |
| Coronary heart disease | 19 (63.30) | 9 (22.00) | <0.001 |
| Stroke Cause, | 0.241 | ||
| Cardioembolism | 20 (66.70) | 20 (48.80) | |
| Large-artery atherosclerosis | 8 (26.70) | 12 (29.30) | |
| Other determined/ undetermined etiology | 2 (6.70) | 9 (21.95) | |
| Laboratory parameters | |||
| Serum glucose (mmol/L), median (IQR) | 7.75 (6.58, 9.63) | 7.00 (5.75, 8.75) | 0.144 |
| PT (s), median (IQR) | 11.20 (10.80, 11.90) | 11.30 (10.50, 12.45) | 0.944 |
| APTT (s), median (IQR) | 31.65 (29.58, 35.10) | 33.80 (30.15, 36.50) | 0.481 |
| INR, median (IQR) | 0.97 (5.94 1.04) | 0.98 (0.92, 1.08) | 0.898 |
| RBC (×1012 cells/L), median (IQR) | 4.39 (3.95, 4.78) | 4.46 (4.05, 5.00) | 0.247 |
| WBC (×109 cells/L), median (IQR) | 7.31 (6.27, 9.48) | 8.04 (6.03, 10.49) | 0.662 |
| Platelet count (×109 cells/L), mean ± SD | 185.69 ± 62.31 | 225.05 ± 100.98 | 0.063 |
| BNP, median (IQR) | 311.51 (185.82, 395.23) | 171.59 (53.68, 492.21) | 0.279 |
| ALT (IU/L), median (IQR) | 14.00 (10.00, 21.00) | 16.00 (12.00, 23.50) | 0.250 |
| AST (IU/L), median (IQR) | 20.50 (16.00, 24.92) | 18.00 (15.00, 22.50) | 0.299 |
| Creatinine (μmol/L), median (IQR) | 78.50 (63.50, 102.00) | 67.00 (60.50, 84.00) | 0.099 |
| Imaging examination | |||
| ASPECTS, median (IQR) | 6.00 (4.00, 8.00) | 8.00 (5.50, 8.00) | 0.151 |
| HMCAS, median (IQR) | 16(53.30) | 19(46.30) | 0.561 |
| Clot burden score, median (IQR) | 3.00 (1.00, 6.00) | 9.00 (4.00, 10.00) | <0.001 |
| Collateral score, | 0.010 | ||
| Good collaterals | 24 (80.00) | 20 (50.00) | |
| Poor collaterals | 6 (20.00) | 20 (50.00) | |
| Occlusion site | 0.001 | ||
| Distal | 2 (6.67) | 13 (31.71) | |
| MCA | 7 (23.33) | 18 (43.90) | |
| ICA | 17 (56.67) | 8 (19.51) | |
| Tandem occlusion (ICA1 MCA M1/M2) | 4 (13.33) | 2 (4.88) | |
NIHSS, National Institute of Health Stroke Scale; SBP, Systolic blood pressure; DBP, Diastolic blood pressure; AF, atrial fibrillation; PT, Prothrombin time; APTT, stands for Activated partial thromboplastin time; INR, International normalized ratio; RBC, Red blood cells; WBC, White blood cells; BNP, B-natriuretic peptide; ALT, stands for Alanine transaminase; AST, Aspartate transaminase; ASPECTS, Alberta stroke program early CT score; HMCAS, hyperdense middle cerebral artery sign; MCA, middle cerebral artery; ICA, internal carotid artery; IQR, interquartile range.
Data of endovascular treatments.
| IV rtPA | 20 (66.67) | 26 (68.42) | 0.878 |
| Onset to puncture (min), median (IQR) | 257.50 (187.75, 351.49) | 303.00 (180.00, 585.57) | 0.154 |
| Puncture to recanalization (min), median (IQR) | 67.00 (41.00, 120.49) | 70.00 (51.50, 120.50) | 0.972 |
| mTICI grade | 0.842 | ||
| <2b | 6 (20.00) | 9 (21.95) | |
| 2b-3 | 24 (80.00) | 32 (78.05) | |
| Passes of the thrombectomy device | 0.887 | ||
| ≤3 | 26 (86.67) | 36 (87.80) | |
| >3 | 4 (13.33) | 5 (12.20) | |
| Mode of endovascular treatment, | 0.079 | ||
| CA | 10 (33.33) | 7 (17.07) | |
| Solumbra | 11 (36.67) | 10 (24.39) | |
| SR | 5 (16.67) | 18 (43.90) | |
| PTAS | 4 (13.33) | 6 (14.63) | |
| Follow-up infarct volume (52 patients) (ml), mean ± SD | 147.07 ± 125.51 | 61.57 ± 97.07 | 0.001 |
| Poor outcome (mRS score, 3–6) | 23 (76.70) | 17 (41.5) | 0.003 |
IV rtPA, concomitant treatment with intravenous recombinant tissue-type plasminogen activator, mTICI, modified thrombolysis in cerebral infarction scale; CA, contact aspiration; SR, stent retriever; PTAS, percutaneous transluminal angioplasty and/or stenting; mRS, modified rankin scale.
Figure 1Good collateral case. One 48-year-old female patient suddenly suffered from inability to lift left upper limb for 30 min. She had an initial NIHSS score of 11 and a mRS score of 0 after 3 months. 4D CTA (A–F) showed occlusion of right middle cerebral artery, and complete collateral circulation before venous phase. Thus, the patient got a 4D CTA collateral circulation score of 4. The T2 star (G) and T2WI (H) on day 6 showed a small acute infarct lesion without hemorrhage transformation.
Figure 2Poor collateral case. One 84-year-old female patient suddenly suffered from inability to lift left upper limb for 1.5 h. She had an initial NIHSS score of 11 and a mRS score of 4 after 3 months. 4D CTA (A–F) showed occlusion of right distal carotid artery and right middle cerebral artery, and few collateral vessels in the lesion side in any phase. Thus, the patient got a 4D CTA collateral circulation score of 0. The T2 star (G) and T2WI (H) on day 7 showed a large acute infarct lesion with hemorrhage transformation.
Multivariate logistic regression analysis of risk factors for HT.
| Age (years) | 0.70 | 0.70 | 1.64 | 0.200 | 2.01 | 0.51–7.93 |
| AF history | 0.85 | 0.09 | 32.94 | <0.001 | 2.35 | 1.96–2.82 |
| NIHSS | 0.69 | 0.08 | 45.92 | <0.001 | 2.00 | 1.72–2.32 |
| Serum glucose (mmol/L) | 0.53 | 0.04 | 76.20 | <0.001 | 1.70 | 1.57–1.85 |
| ASPECTS | 0.92 | 0.58 | 0.05 | 0.817 | 2.50 | 0.80–7.82 |
| Collateral score | −0.27 | 0.02 | 121.44 | <0.001 | 0.76 | 0.73–0.80 |
| Occlusion site | 1.04 | 0.66 | 0.60 | 0.438 | 2.84 | 0.78–10.38 |
| Clot burden score | 0.01 | 0.17 | 0.581 | 0.446 | 1.01 | 0.72–1.41 |
SE, Standard error; OR, odds ratios; CI, confidence interval; AF, atrial fibrillation.
Figure 3Forest plot of hemorrhage transformation after endovascular treatments. NIHSS, National Institute of Health Stroke Scale; AF, atrial fibrillation; ASPECTS, Alberta stroke program early CT score; OR, odds ratios.
Figure 4ROC curves of atrial fibrillation history, NIHSS, collateral score and serum glucose to predict the HT. NIHSS, National Institute of Health Stroke Scale; AF, atrial fibrillation.